Publications by authors named "Melina Arazy"
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
March 2022
Article Synopsis
- - In the phase 3 BOSTON study, patients with multiple myeloma (MM) received either weekly selinexor combined with bortezomib-dexamethasone (XVd) or the standard twice-weekly bortezomib-dexamethasone (Vd), with XVd showing significant improvements in progression-free survival (PFS) and overall response rate (ORR).
- - Results indicated that patients with high-risk MM had a median PFS of 12.91 months with XVd compared to 8.61 months with Vd, and ORRs were 78.6% for XVd versus 57.7% for Vd.
- - The study
Article Synopsis
- Therapeutic options for previously treated multiple myeloma have limited effectiveness and can cause serious side effects, like peripheral neuropathy.
- In the Phase 3 BOSTON study, the combination of selinexor, bortezomib, and dexamethasone (XVd) significantly outperformed the standard treatment (Vd) in terms of progression-free survival, response rates, and severity of side effects.
- XVd showed the most benefits for patients with fewer previous treatments, especially those who hadn't received a proteasome inhibitor or prior stem cell transplant, suggesting it may be a better option for early treatment phases.
Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial.
View Article and Find Full Text PDFBackground: Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multiple myeloma.
View Article and Find Full Text PDF